TEK and pneumonia: Tie-2 receptor antagonists including Vasculotide and AV-001 (Vasomune therapeutics) have shown promise in animal models of sepsis and influenza [39,40]; a phase 2a study of AV-001 in adults with pneumonia is underway [41], but others including the Ang-2 binding and Tie-2 activating antibody (ABTAA) have also shown promise in preclinical models of sepsis [42].